Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2012 Jan 16;24(6):705–712. doi: 10.1592/phco.24.8.705.36063

Severe Acute Respiratory Syndrome (SARS): The Pharmacist's Role

Thomas W F Chin 1,2,4,, Clarence Chant 1,3,4, Rosemary Tanzini 1, Janice Wells 1
PMCID: PMC7167812  PMID: 15222659

Abstract

Objectives. After two outbreaks of severe acute respiratory syndrome (SARS) occurred in Toronto, Ontario, Canada, from March–June 2003, we reviewed the unexpected role and responsibilities of pharmacists during these two crises, and present strategies for better crisis preparedness.

Methods and Results. Pharmacists were actively involved in battling the SARS crises. After conducting extensive literature searches and evaluations, pharmacists prepared administration and dosing guidelines for the two investigational drugs, ribavirin and interferon alfacon‐1, that were being used to treat the syndrome. They provided direct patient care under modified conditions. They revised drug distribution procedures and developed new ones to meet more stringent infection‐control standards. Collaborative teamwork with key stakeholders was important in accomplishing tasks in an efficient and timely manner. Regular communication with health care staff took place internally and externally. Education and updated information for pharmacists was crucial.

Conclusion. Pharmacists can play a vital role during crises in the areas of drug distribution, drug information, and direct patient care. Collaborative teamwork and close communication are keys to success. Pharmacists must be proactive and take a leadership role in assuming pharmacy‐related responsibilities. By evaluating what worked and what didn't, pharmacists can develop procedures for future crises requiring pharmacy support.

Keywords: severe acute respiratory syndrome, SARS crisis, pharmacist's role, preparedness

References

  • 1. Health Canada. SARS (severe acute respiratory syndrome) outbreak period. Available from http://www.hc-sc.gc.ca/pphb-dgspsp/sars-sras/sars.html. Accessed December 31, 2003.
  • 2. World Health Organization. Cumulative number of reported probable cases of SARS. Available from http://www.who.int/csr/sars/country/table2003_09_23/en. Accessed December 31, 2003.
  • 3. Booth, C.M. , Matukas, L.M. , Tomlinson, G.A. , et al. Clinical features and short‐term outcomes of 144 patients with SARS in the Greater Toronto Area. JAMA 2003;289: 2801–9. [DOI] [PubMed] [Google Scholar]
  • 4. Peiris, J.S.M. , Lai, S.T. , Poon, L.L.M. , et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361: 1319–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Ksiazek, T.G. , Erdman, D. , Goldsmith, C.S. , et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348: 1953–66. [DOI] [PubMed] [Google Scholar]
  • 6. Drosten, C. , Gunther, S. , Preiser, W. , et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348: 1967–76. [DOI] [PubMed] [Google Scholar]
  • 7. Poutanen, S.M. , Low, D.E. , Henry, B. , et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348: 1995–2005. [DOI] [PubMed] [Google Scholar]
  • 8. Tsang, K.W. , Ho, P.L. , Yee, W.K. , et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348: 1977–85. [DOI] [PubMed] [Google Scholar]
  • 9. Lee, N. , Hui, D. , Wu, A. , et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348: 1986–94. [DOI] [PubMed] [Google Scholar]
  • 10. ICN Pharmaceuticals Inc. Intravenous ribavirin, IND 9076, investigational drug brochure. Costa Mesa, CA; 2001.
  • 11. InterMune Inc. Infergen (interferon alfacon‐1) package insert. Brisbane, CA; 2002.
  • 12. Loutfy, M.R. , Blatt, L.M. , Siminovitch, K.A. , et al. Interferon alfacon‐1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003;290: 3222–8. [DOI] [PubMed] [Google Scholar]
  • 13. Centers for Disease Control and Prevention. Terrorism preparedness compendium. Available from http://www.cdc.gov/mmwr. Accessed August 2003.
  • 14. Burda, A.M. , Sigg, T. Pharmacy preparedness for incidents involving weapons of mass destruction. Am J Health-Syst Pharm 2001;58: 2274–84. [DOI] [PubMed] [Google Scholar]
  • 15. Terriff, C.M. , Tee, A.M. Citywide pharmaceutical preparation for terrorism. Am J Health-Syst Pharm 2001;58: 233–7. [DOI] [PubMed] [Google Scholar]
  • 16. Teeter, D.S. Bioterrorism preparedness: answers for the health‐system pharmacist. Am J Health-Syst Pharm 2002;59: 928–30. [DOI] [PubMed] [Google Scholar]
  • 17. Laughrun, G.M. Preparing your hospital to respond to a terrorist attack. Am J Health-Syst Pharm 2002;59: 1329–30. [DOI] [PubMed] [Google Scholar]
  • 18. Young, D. Experience with disaster yields lessons in preparedness. Am J Health-Syst Pharm 2002;59: 1814–16. [DOI] [PubMed] [Google Scholar]
  • 19. Gaudette, R. , Schnitzer, J. , George, E. , Briggs, S.M. Lessons learned from the September 11th World Trade Center disaster: pharmacy preparedness and participation in an international medical and surgical response team. Pharmacotherapy 2002;22: 271–81. [DOI] [PubMed] [Google Scholar]
  • 20. Terriff, C.M. , Schwartz, M.D. , Lomaestro, B.M. Bioterrorism: pivotal clinical issues: consensus review of the society of infectious diseases pharmacists. Pharmacotherapy 2003;23: 274–90. [DOI] [PubMed] [Google Scholar]

Articles from Pharmacotherapy are provided here courtesy of Wiley

RESOURCES